• Je něco špatně v tomto záznamu ?

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force

C. de la Fouchardière, A. Cammarota, M. Svrcek, M. Alsina, T. Fleitas-Kanonnikoff, R. Lordick Obermannová, AD. Wagner, D. Yap Wei Ting, D. Enea, A. Petrillo, EC. Smyth

. 2025 ; 134 (-) : 102890. [pub] 20250201

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009642

In less than a decade, immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI) cancers. However, beyond colorectal cancer (CRC), much of the evidence is mostly derived from non-randomized phase II studies or post-hoc analyses of broader clinical trials. dMMR/MSI tumours represent a specific subgroup of gastro-esophageal adenocarcinomas (GEA), accounting for approximately 9 % of cases, with a higher prevalence in early-stage compared to advanced-stage disease and older female patients. These tumours are predominantly sporadic, often linked to MLH1 promoter methylation, and rarely exhibit HER2 overexpression/ERBB2 amplification or other oncogenic drivers. The treatment landscape for early stage dMMR/MSI GEA is likely to change substantially soon, as ICIs have shown high pathological complete response (pCR) rates in small phase II trials, raising questions on optimisation of neoadjuvant therapy, and paving the way for organ preservation. The standard of treatment for untreated patients with advanced dMMR/MSI GEA is chemotherapy + ICI irrespectively of PDL-1 status. However, the role of chemotherapy-free regimen consisting of CTLA-4 plus PD-1 inhibitors remains undetermined. This review addresses these and other emerging questions, offering expert opinions and insights into the future therapeutic landscape for dMMR/MSI GEA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009642
003      
CZ-PrNML
005      
20250429134533.0
007      
ta
008      
250415e20250201ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ctrv.2025.102890 $2 doi
035    __
$a (PubMed)39933210
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a de la Fouchardière, Christelle $u Institut PAOLI-CALMETTES, 232 Boulevard Sainte-Marguerite 13009, Marseille, France; Unicancer GI (UCGI) Group, Paris, France; EORTC-GITC Group, Brussels, Belgium. Electronic address: delafouchardierec@ipc.unicancer.fr
245    10
$a How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force / $c C. de la Fouchardière, A. Cammarota, M. Svrcek, M. Alsina, T. Fleitas-Kanonnikoff, R. Lordick Obermannová, AD. Wagner, D. Yap Wei Ting, D. Enea, A. Petrillo, EC. Smyth
520    9_
$a In less than a decade, immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI) cancers. However, beyond colorectal cancer (CRC), much of the evidence is mostly derived from non-randomized phase II studies or post-hoc analyses of broader clinical trials. dMMR/MSI tumours represent a specific subgroup of gastro-esophageal adenocarcinomas (GEA), accounting for approximately 9 % of cases, with a higher prevalence in early-stage compared to advanced-stage disease and older female patients. These tumours are predominantly sporadic, often linked to MLH1 promoter methylation, and rarely exhibit HER2 overexpression/ERBB2 amplification or other oncogenic drivers. The treatment landscape for early stage dMMR/MSI GEA is likely to change substantially soon, as ICIs have shown high pathological complete response (pCR) rates in small phase II trials, raising questions on optimisation of neoadjuvant therapy, and paving the way for organ preservation. The standard of treatment for untreated patients with advanced dMMR/MSI GEA is chemotherapy + ICI irrespectively of PDL-1 status. However, the role of chemotherapy-free regimen consisting of CTLA-4 plus PD-1 inhibitors remains undetermined. This review addresses these and other emerging questions, offering expert opinions and insights into the future therapeutic landscape for dMMR/MSI GEA.
650    _2
$a lidé $7 D006801
650    12
$a adenokarcinom $x farmakoterapie $x genetika $x patologie $x terapie $7 D000230
650    12
$a nádory jícnu $x farmakoterapie $x genetika $x patologie $7 D004938
650    12
$a mikrosatelitní nestabilita $7 D053842
650    12
$a nádory žaludku $x farmakoterapie $x genetika $x patologie $x terapie $7 D013274
650    12
$a oprava chybného párování bází DNA $7 D053843
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Cammarota, Antonella $u EORTC-GITC Group, Brussels, Belgium; Hepatobiliary Immunopathology Lab, Humanitas University, Pieve Emanuele, Milan, Italy
700    1_
$a Svrcek, Magali $u Sorbonne Université, AP-HP, Saint-Antoine Hospital, Department of Pathology, France; LIMICS, UMRS 1142, Campus des Cordeliers 75006, Paris, France
700    1_
$a Alsina, Maria $u EORTC-GITC Group, Brussels, Belgium; Hospital Universitario de Navarra, Navarrabiomed - IdiSNA, c. de Irunlarrea 3 31008, Pamplona, Spain
700    1_
$a Fleitas-Kanonnikoff, Tania $u EORTC-GITC Group, Brussels, Belgium; Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain
700    1_
$a Lordick Obermannová, Radka $u EORTC-GITC Group, Brussels, Belgium; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Czech Republic
700    1_
$a Wagner, Anna Dorothea $u EORTC-GITC Group, Brussels, Belgium; Anna Dorothea Wagner, Department of Oncology, Division of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), 1011, Lausanne, Switzerland
700    1_
$a Yap Wei Ting, Dominic $u National University of Singapore - Yong Loo Lin School of Medicine, Singapore
700    1_
$a Enea, Diana $u Sorbonne Université, AP-HP, Saint-Antoine Hospital, Department of Pathology, France
700    1_
$a Petrillo, Angelica $u EORTC-GITC Group, Brussels, Belgium; Medical Oncology Unit, Ospedale del Mare, Naples, Italy
700    1_
$a Smyth, Elizabeth C $u EORTC-GITC Group, Brussels, Belgium; Oxford NIHRBiomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK
773    0_
$w MED00001047 $t Cancer treatment reviews $x 1532-1967 $g Roč. 134 (20250201), s. 102890
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39933210 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134529 $b ABA008
999    __
$a ok $b bmc $g 2311173 $s 1246723
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 134 $c - $d 102890 $e 20250201 $i 1532-1967 $m Cancer treatment reviews $n Cancer Treat Rev $x MED00001047
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace